Levels of the Novel Endogenous Antagonist of Ghrelin Receptor, Liver-Enriched Antimicrobial Peptide-2, in Patients with Rheumatoid Arthritis.
ghrelin
growth hormone secretagogue receptor 1a
liver-expressed antimicrobial peptide 2
rheumatoid arthritis
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
06 Apr 2020
06 Apr 2020
Historique:
received:
03
03
2020
revised:
31
03
2020
accepted:
04
04
2020
entrez:
10
4
2020
pubmed:
10
4
2020
medline:
7
1
2021
Statut:
epublish
Résumé
Rheumatoid arthritis (RA) is a debilitating, chronic, inflammatory, autoimmune disease associated with cachexia. The substitutive therapy of gut hormone ghrelin has been pointed at as a potential countermeasure for the management of metabolic and inflammatory complications in RA. The recent discovery of liver-expressed antimicrobial peptide 2 (LEAP2) as an endogenous inverse agonist/antagonist of the ghrelin receptor makes feasible the development of a more rational pharmacological approach. This work aimed to assess the serum LEAP2 levels, in a cohort of RA patients, in comparison with healthy individuals and determine its correlation with inflammatory parameters. LEAP2 levels were determined by a commercial ELISA kit, plasma C-reactive protein (CRP) levels were evaluated using immunoturbidimetry, and serum levels of inflammatory mediators, namely IL-6, IL-8, IL-1β, MIP1α, MCP1, and LCN2, were measured by XMap multiplex assay. LEAP2 serum levels were significantly increased in RA patients (
Identifiants
pubmed: 32268520
pii: nu12041006
doi: 10.3390/nu12041006
pmc: PMC7231392
pii:
doi:
Substances chimiques
Antimicrobial Cationic Peptides
0
Biomarkers
0
Blood Proteins
0
Cytokines
0
Receptors, Ghrelin
0
liver-expressed antimicrobial peptide 2, human
0
C-Reactive Protein
9007-41-4
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Cell Immunol. 2010;261(2):128-33
pubmed: 20038463
Vitam Horm. 2013;92:61-106
pubmed: 23601421
Rheumatology (Oxford). 2004 Mar;43(3):306-10
pubmed: 14623951
Arthritis Rheum. 2009 Jun;60(6):1704-9
pubmed: 19479831
Lancet Oncol. 2016 Apr;17(4):519-531
pubmed: 26906526
Endocrinology. 2005 Mar;146(3):1285-92
pubmed: 15576457
Trends Pharmacol Sci. 2018 Aug;39(8):685-694
pubmed: 30037389
Cell Metab. 2018 Feb 6;27(2):461-469.e6
pubmed: 29233536
World J Gastroenterol. 2012 Jun 7;18(21):2674-81
pubmed: 22690077
Nat Rev Dis Primers. 2018 Feb 08;4:18001
pubmed: 29417936
J Clin Invest. 2019 Sep 3;129(9):3909-3923
pubmed: 31424424
Rheumatology (Oxford). 2014 Feb;53(2):205-12
pubmed: 23882111
Front Nutr. 2014 Nov 24;1:20
pubmed: 25988122
Int J Mol Sci. 2017 Apr 11;18(4):
pubmed: 28398233
FASEB J. 2018 Feb;32(2):1044-1058
pubmed: 29070587